First, as local control with stereotactic radiosurgery (SRS) is better for smaller than larger tumors, the ability of combined BRAF and MEK inhibition to reduce tumor size in most patients may augment the efficacy of SRS. The gene discussed is MAP2K7; the disease is neoplasm.